Magnesium stearate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name

Magnesium stearate

DrugBank Accession Number

DB14077

Background

Not Available

Type

Small Molecule

Groups

Investigational

Structure

Similar Structures

Weight: Average: 591.244
Monoisotopic: 590.512452626
Chemical Formula: C₃₆H₇₀MgO₄

Synonyms

Dibasic magnesium stearate
Magnesium distearate
Magnesium octadecanoate
Octadecanoic acid, magnesium salt
Stearic acid, magnesium salt

External IDs

SM 1000

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication: Not Available
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">: Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Atracurium	The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium stearate.
Atracurium besylate	The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium stearate.
Botulinum toxin type A	The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Magnesium stearate.
Botulinum toxin type B	The risk or severity of adverse effects can be increased when Magnesium stearate is combined with Botulinum toxin type B.
Capreomycin	The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Magnesium stearate.

Food Interactions

Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Daycling	Tablet	5 mg/1	Vaginal	Istk3	2017-10-24	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Medi Megaton 2080	Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g)	Powder	Topical	Mbg Inc (Korea Institute of Science Development)	2016-10-15	2017-10-15
Medi Megaton 2080	Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g)	Powder	Topical	Mbg Inc (Korea Institute of Science Development)	2016-10-16	2017-10-16
SAMTACID	Magnesium stearate (200 mg/5ml) + Aluminum hydroxide (200 mg/5ml) + Simethicone (30 mg/5ml)	Suspension		Samco Farma	2017-03-03	2024-02-14

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Daycling	Magnesium stearate (5 mg/1)	Tablet	Vaginal	Istk3	2017-10-24	Not applicable
Medi Megaton 2080	Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g)	Powder	Topical	Mbg Inc (Korea Institute of Science Development)	2016-10-15	2017-10-15
Medi Megaton 2080	Magnesium stearate (0.005 g/100g) + Glycerin (0.002 g/100g) + Saw palmetto (0.01 g/100g) + Silicon dioxide (0.01 g/100g) + Titanium dioxide (0.001 g/100g) + Zinc oxide (0.0146 g/100g)	Powder	Topical	Mbg Inc (Korea Institute of Science Development)	2016-10-16	2017-10-16

Chemical Identifiers

UNII: 70097M6I30
CAS number: 557-04-0
InChI Key: HQKMJHAJHXVSDF-UHFFFAOYSA-L
InChI: InChI=1S/2C18H36O2.Mg/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;/h2*2-17H2,1H3,(H,19,20);/q;;+2/p-2
IUPAC Name: magnesium(2+) dioctadecanoate
SMILES: [Mg++].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O

References

General References

Not Available

External Links

KEGG Drug: D02189
ChemSpider: 10704
RxNav: 1310567
ChEBI: 9254
ChEMBL: CHEMBL2106633
Wikipedia: Magnesium_stearate

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
2	Recruiting	Treatment	Coronavirus Disease 2019 (COVID‑19)	1
1	Completed	Supportive Care	Stable COPD Patients	1
1	Completed	Treatment	Asthma	1
1	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
1	Completed	Treatment	Healthy Subjects (HS)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Tablet	Vaginal	5 mg/1
Tablet	Oral
Powder	Topical
Suspension

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	1.13e-05 mg/mL	ALOGPS
logP	10.89	ALOGPS
logP	7.15	Chemaxon
logS	-7.7	ALOGPS
pKa (Strongest Acidic)	4.95	Chemaxon
Physiological Charge	-1	Chemaxon
Hydrogen Acceptor Count	2	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	40.13 Å²	Chemaxon
Rotatable Bond Count	32	Chemaxon
Refractivity	97.12 m³·mol^-1	Chemaxon
Polarizability	38.18 Å³	Chemaxon
Number of Rings	0	Chemaxon
Bioavailability	0	Chemaxon
Rule of Five	No	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST): Not Available
Spectra: Not Available
Chromatographic Properties: Collision Cross Sections (CCS)
Not Available

Drug created at June 17, 2018 16:58 / Updated at June 12, 2020 16:53

Magnesium stearate

Identification

Structure for Magnesium stearate (DB14077)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)